Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

MEDIA ALERT: ESMO Asia 2015 Congress Preview

Cancer experts share latest insights in Singapore
16 Dec 2015

LUGANO/SINGAPORE, 16 December 2015 – ESMO, the leading professional organisation for medical oncology, is pleased to announce the inaugural ESMO Asia 2015 Congress in Singapore. A premier scientific and educational platform for oncologists and other stakeholders in cancer care, the Asian edition of ESMO’s annual congress aims to facilitate information exchange between researchers, clinicians and patients across disciplines to find the most effective treatment solutions.

Please find below short summaries of the news that will be released in connection with the ESMO Asia 2015 Congress.

Press releases will be issued on a daily basis.

Underprivileged patients at major risk of disease-related ‘financial catastrophe’

[Under EMBARGO until Thursday 17 December, 23:55 hrs SGT]

Data collected in 8 low and middle-income South-East Asian countries shows 5% of cancer patients were pushed into poverty because of the high disease-related costs (March 2012-September 2013). The researchers showed that cancer resulted in ‘financial catastrophe’ for almost half of the patients with economic hardship at the time of diagnosis. 

Immunotherapy and targeted therapy: new options for difficult-to-treat head-and-neck cancers

[Under EMBARGO until Thursday 17 December, 23:55 hrs SGT]

Phase I and II trials show promising antineoplastic activity of the immunotherapy agent pembrolizumab in patients with heavily pretreated nasopharyngeal cancer, and effectiveness of the targeted agent afatinib as second-line treatment for recurrent or metastatic squamous cell carcinoma (HNSCC) after failure with platinum-based therapy.

Asian women with endocrine-resistant breast cancer benefit from combination therapy

[Under EMBARGO until Friday 18 December, 23:55 hrs SGT]

Data collected for Japanese and Korean patients in a global trial provides evidence for combining palbociclib with fulvestrant to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

Afatinib a better choice for EGFR-mutated lung cancer in first-line

[Under EMBARGO until Saturday 19 December, 23:55 hrs SGT]

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib as first-line treatment across a range of clinically relevant endpoints, as reported in a global, randomised, open-label Phase IIb trial. 

More patients with lung cancer could benefit from immunotherapy

[Under EMBARGO until Saturday 19 December, 23:55 hrs SGT]

Pivotal phase 2/3 trial shows that two doses of the anti-PD-1 antibody pembrolizumab and a higher, investigational dose improve median survival in all PD-L1-positive patients compared with the commonly used chemotherapy. 

Get a first glimpse of what you can expect from the Congress: abstracts accepted for Poster, Poster Discussion and Proffered Paper sessions at the ESMO Asia 2015 Congress are available online (as of Wednesday, 16 December 2015 at 16:00 hrs SGT).

View the online programme

Late-breaking abstracts will be made public at the beginning of the official Congress session during which they are presented. 

Media Registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration to the ESMO Asia 2015 Congress is free to bona fide journalists on presentation of a letter of assignment and a valid press card (ESMO Media Policy).

We are looking forward to welcoming you in Singapore or to help you with any inquiry about remote coverage of ESMO Asia 2015.

The ESMO Press Office Team

Last update: 16 Dec 2015

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings